
About Zim Labs
Zim Labs is a publicly listed company based in Nagpur (India) founded in 1989. Solid and semisolid dosage forms are developed and manufactured. Zim Labs has raised $8.2 million across 2 funding rounds from investors including Ashmore. The company has 577 employees. Its website zimlab.in draws about 12 thousand monthly visits. Its Indian entity Zim Laboratories Limited. reported revenue of βΉ386 Cr. Zim Labs offers products and services including Oral Thin Films, Pre-Formulation Intermediates, and Finished Formulations. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its competitors include Inventia Healthcare and Halewood Laboratories; 1 of its 2 listed competitors has raised funding.
Company details
Zim Labs was founded in 1989 and is based in Nagpur, India, within the pharmaceutical sector. Various solid and semisolid dosage forms, such as granules, pellets with sustained, modified, or extended release, taste-masked powders, suspensions, tablets, capsules, and oral thin films, are developed and manufactured. Services provided include drug release modifications, solubility enhancement, and taste masking for pharmaceutical applications.
- Market Cap₹799 Cr
ZIMLAB · NSE
- Share Price₹147.80
-0.69% today
- Revenue₹374 Cr
FY 2025-26 · -1.2% YoY
- EBITDA₹30.01 Cr
Margin 8.0%
- Net Profit₹4.35 Cr
FY 2025-26 · -63.5% YoY
- P/E (TTM)350.9x
P/B 2.5x
- ROE1.6%
ROCE 4.8%
- Debt / Equity0.45
Interest cover 131.6x
- Total Equity Funding$8.2M (USD)
in 2 rounds
- Investors
- Employee Count577
Associated legal entities of Zim Labs
Zim Labs operates through Zim Laboratories Limited., a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Zim Laboratories Limited. Listed CIN L99999MH1984PLC032172 | Active | 14 Feb 1984 | Nagpur, Maharashtra | ₹386 Cr | 586 | 10 | View details |
Products & Services of Zim Labs
Zim Labs offers a comprehensive portfolio of products and services, including Oral Thin Films, Pre-Formulation Intermediates, and Finished Formulations.
Provides drug delivery films for patient convenience and adherence.
Offers granules and pellets for generic product development.
Supplies tablets and capsules for regulated markets.
Apps and channels of Zim Labs
its YouTube channel ZIM Laboratories has 506 subscribers and 30 videos.
Videos from Zim Labs
The most watched videos on Zim Labs's YouTube channel, ZIM Laboratories (506 subscribers). Click a video to play it here.
More on ZIM Laboratories.
Funding Insights of Zim Labs
Zim Labs has successfully raised a total of $8.2M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.2M
- Total Rounds 2
- First Round $8.2M
(Jan 2013)
- Investors Count 1
All 2 funding rounds of Zim Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2021 | Grant | β | β | β | |
| Jan 2013 | $8.2M | Series A | β | β |
1 investors in total: 1 institutional.
Investors in Zim Labs
Zim Labs has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ashmore.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management services are provided by Ashmore globally. | 1992 | ashmoregroup.com | London, United Kingdom |
Investor details for Zim Labs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Zim Laboratories Limited. (Zim Labs)
Zim Laboratories Limited. is the primary company behind Zim Labs. The board of Zim Laboratories Limited. currently have 8 directors; the longest-serving is Anwar Siraj Daud, appointed in 2009. 14 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Anwar Siraj Daud DIN 00023529 | Managing Director | 01 Apr 2009 | 17 yrs 7 mo | Zim Laboratories Limited. |
| Zulfiquar Murtaza Kamal DIN 01786763 | Whole-time director | 19 Oct 2012 | 14 yrs 1 mo | Zim Laboratories Limited. |
| Prakash Pralahadrao Sapkal DIN 02007385 | Whole-time director | 22 Nov 2013 | 12 yrs 11 mo | Zim Laboratories Limited. |
| Niraj Pukhraj Dhadiwal DIN 02007428 | Whole-time director | 22 Nov 2013 | 12 yrs 11 mo | Zim Laboratories Limited. |
| Kavita Loya DIN 07943519 | Director | 21 Sep 2017 | 9 yrs 1 mo | Zim Laboratories Limited. |
| Padmakar Shrinivas Joshi DIN 07944709 | Director | 21 Sep 2017 | 9 yrs 1 mo | Zim Laboratories Limited. |
| Kamlesh Bajirao Shende DIN 09537666 | Director | 01 Apr 2022 | 4 yrs 7 mo | Zim Laboratories Limited. |
| Ashok Bhatia DIN 02090239 | Director | 01 Apr 2025 | 1 yr 7 mo | Zim Laboratories Limited. |
People of Zim Labs
14 people are tracked at Zim Labs (2 in leadership, 9 in board & advisors, 3 in team); the tracked headcount is 577.
| Name | Role | Group |
|---|---|---|
Shyam Mohan Patro | CFO, Accounts & Finance | Leadership |
Pradeep Kataria | Senior Vice President | Leadership |
Chandrashekhar Mainde | Director | Board & advisors |
Gautam Saigal | Director | Board & advisors |
| Director | Board & advisors | |
| Director | Board & advisors | |
| Director | Board & advisors | |
| Director | Board & advisors | |
| Director | Board & advisors | |
| Director | Board & advisors | |
Kakasaheb Mahadik | Director | Board & advisors |
DEEPENDRA MAHULE | EA to MD | Team |
Bhushan Shukla | Manager | Team |
| Chairman & MD | Team |
Complete people profiles for Zim Labs
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Zim Labs
Zim Labs is a publicly listed company on the NSE with ticker symbol ZIMLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Nov 2022
- Listed onNSE: ZIMLAB
- Listed entityZim Laboratories Ltd.
- Exchange sectorHealth technology
- ISININE518E01015
- Share price₹146.78 (+0.01% on the day) · 2026-10-14
- Market capitalisation₹789 Cr
- Price to earnings177.9
- EPS (diluted, trailing year)₹0.83
- Volume (last session)68,587
Financials of Zim Labs
Exchange-reported figures of Zim Laboratories Limited., the listed company behind Zim Labs (NSE: ZIMLAB).
Financial Highlights
FY 2025-26 Β· ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 374 | 379 | 367 | 399 | 333 | 307 | 278 |
| Revenue growth | -1.2% | +3.2% | -7.8% | +19.5% | +8.5% | +10.6% | - |
| EBITDA | 30.01 | 43.72 | 41.33 | 51.99 | 40.97 | 34.58 | 22.62 |
| EBITDA margin | +8.0% | +11.5% | +11.3% | +13.1% | +12.3% | +11.3% | +8.1% |
| Profit before tax | 8.21 | 18.00 | 23.64 | 35.35 | 21.03 | 10.23 | 0.08 |
| Net profit | 4.35 | 11.92 | 17.26 | 24.43 | 14.54 | 11.03 | 3.31 |
| Net profit margin | +1.2% | +3.1% | +4.7% | +6.1% | +4.4% | +3.6% | +1.2% |
| EPS (βΉ) | 1.09 | 2.50 | 3.54 | 5.01 | 8.96 | 4.51 | 2.04 |
| Balance sheet | |||||||
| Total assets | 423 | 370 | 351 | 262 | 229 | 243 | 244 |
| Net worth | 296 | 252 | 239 | 200 | 176 | 161 | 154 |
| Total debt | 127 | 118 | 112 | 62.16 | 53.44 | 82.32 | 89.85 |
| Cash & bank | 43.41 | 2.49 | 10.46 | 7.52 | 4.97 | 8.35 | 3.95 |
| Net working capital | 170 | 140 | 141 | 117 | 100 | 110 | 101 |
| Cash flow | |||||||
| Cash from operations | 49.53 | 41.15 | 16.28 | 37.52 | 49.21 | 31.85 | 21.92 |
| Cash from investing | (54.54) | (39.70) | (72.63) | (35.06) | (14.21) | (5.95) | (18.44) |
| Cash from financing | 28.19 | (9.10) | 59.53 | 0.55 | (32.97) | (25.97) | (2.51) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105 | 94.18 | 105 | 109 | 88.71 | 71.76 | 109 | 96.33 |
| Revenue growth (YoY) | +18.9% | +31.2% | -3.2% | +12.8% | -3.7% | -12.3% | - | - |
| Other income | 2.30 | 0.99 | 6.16 | 1.70 | 2.04 | 1.48 | 1.71 | 1.75 |
| EBITDA | 5.43 | 2.45 | 7.19 | 12.81 | 5.75 | 4.26 | 14.59 | 11.56 |
| EBITDA margin | +5.1% | +2.6% | +6.8% | +11.8% | +6.5% | +5.9% | +13.4% | +12.0% |
| Depreciation | 6.53 | 5.37 | 5.10 | 5.03 | 4.98 | 4.86 | 5.29 | 4.88 |
| Interest | 3.94 | 3.64 | 3.31 | 3.43 | 3.16 | 3.30 | 2.91 | 2.73 |
| Profit before tax | (2.74) | (5.57) | 4.94 | 6.05 | (0.35) | (2.42) | 8.10 | 5.70 |
| Tax | (0.69) | (1.56) | 1.20 | 1.65 | 0.08 | (0.55) | 3.22 | 1.71 |
| Net profit | (2.05) | (4.01) | 3.74 | 4.40 | (0.43) | (1.87) | 4.88 | 3.99 |
| EPS (βΉ) | (0.38) | (0.75) | 0.76 | 0.90 | (0.09) | (0.38) | 1.01 | 0.82 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 370 | 376 | 365 | 397 | 329 | 304 | 274 |
| Revenue growth | -1.4% | +2.8% | -7.8% | +20.4% | +8.5% | +10.7% | - |
| EBITDA | 29.57 | 43.27 | 40.09 | 51.20 | 37.93 | 31.64 | 19.79 |
| EBITDA margin | +8.0% | +11.5% | +11.0% | +12.9% | +11.5% | +10.4% | +7.2% |
| Profit before tax | 8.39 | 17.61 | 23.03 | 35.92 | 19.29 | 8.59 | (1.47) |
| Net profit | 4.39 | 11.66 | 16.76 | 25.01 | 13.01 | 9.01 | 1.76 |
| Net profit margin | +1.2% | +3.1% | +4.6% | +6.3% | +4.0% | +3.0% | +0.6% |
| EPS (βΉ) | 1.11 | 2.41 | 3.44 | 5.13 | 8.01 | 3.46 | 1.08 |
| Balance sheet | |||||||
| Total assets | 413 | 362 | 344 | 256 | 224 | 239 | 242 |
| Net worth | 286 | 245 | 232 | 194 | 170 | 157 | 152 |
| Total debt | 127 | 118 | 112 | 62.16 | 53.44 | 82.32 | 89.85 |
| Cash & bank | 37.00 | 0.82 | 0.75 | 2.21 | 2.09 | 7.86 | 2.83 |
| Net working capital | 151 | 126 | 129 | 105 | 89.07 | 102 | 95.65 |
| Cash flow | |||||||
| Cash from operations | 47.66 | 50.60 | 11.47 | 35.23 | 47.03 | 31.90 | 21.29 |
| Cash from investing | (57.41) | (41.31) | (71.94) | (35.21) | (14.42) | (5.70) | (18.82) |
| Cash from financing | 28.19 | (9.10) | 59.53 | 0.55 | (32.97) | (25.96) | (2.16) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 104 | 93.05 | 103 | 108 | 88.39 | 71.43 | 109 | 95.40 |
| Revenue growth (YoY) | +17.9% | +30.3% | -5.2% | +13.0% | -1.5% | -12.9% | - | - |
| Other income | 2.29 | 0.99 | 6.16 | 1.71 | 2.04 | 1.48 | 1.55 | 1.76 |
| Total expenses | 99.10 | 90.64 | 96.28 | 95.31 | 82.22 | 67.09 | 93.28 | 83.63 |
| EBITDA | 5.12 | 2.41 | 6.57 | 12.50 | 6.17 | 4.34 | 15.24 | 11.77 |
| EBITDA margin | +4.9% | +2.6% | +6.4% | +11.6% | +7.0% | +6.1% | +14.0% | +12.3% |
| Depreciation | 6.26 | 5.17 | 4.90 | 4.85 | 4.83 | 4.79 | 5.23 | 4.77 |
| Interest | 3.94 | 3.64 | 3.31 | 3.43 | 3.16 | 3.30 | 2.91 | 2.73 |
| Profit before tax | (2.79) | (5.41) | 4.52 | 5.93 | 0.22 | (2.27) | 8.65 | 6.03 |
| Tax | (0.65) | (1.55) | 1.24 | 1.67 | 0.11 | (0.59) | 3.23 | 1.68 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105 | 94.18 | 105 | 109 | 88.71 | 71.76 | 109 | 96.33 |
| Revenue growth (YoY) | +18.9% | +31.2% | -3.2% | +12.8% | -3.7% | -12.3% | - | - |
| Other income | 2.30 | 0.99 | 6.16 | 1.70 | 2.04 | 1.48 | 1.71 | 1.75 |
| EBITDA | 5.43 | 2.45 | 7.19 | 12.81 | 5.75 | 4.26 | 14.59 | 11.56 |
| EBITDA margin | +5.1% | +2.6% | +6.8% | +11.8% | +6.5% | +5.9% | +13.4% | +12.0% |
| Depreciation | 6.53 | 5.37 | 5.10 | 5.03 | 4.98 | 4.86 | 5.29 | 4.88 |
| Interest | 3.94 | 3.64 | 3.31 | 3.43 | 3.16 | 3.30 | 2.91 | 2.73 |
| Profit before tax | (2.74) | (5.57) | 4.94 | 6.05 | (0.35) | (2.42) | 8.10 | 5.70 |
| Tax | (0.69) | (1.56) | 1.20 | 1.65 | 0.08 | (0.55) | 3.22 | 1.71 |
| Net profit | (2.05) | (4.01) | 3.74 | 4.40 | (0.43) | (1.87) | 4.88 | 3.99 |
| EPS (βΉ) | (0.38) | (0.75) | 0.76 | 0.90 | (0.09) | (0.38) | 1.01 | 0.82 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 374 | 379 | 367 | 399 | 333 | 307 | 278 |
| Revenue growth | -1.2% | +3.2% | -7.8% | +19.5% | +8.5% | +10.6% | - |
| Other income | 11.38 | 5.78 | 5.18 | 6.41 | 4.40 | 2.34 | 4.52 |
| Total expenses | 344 | 335 | 326 | 347 | 292 | 273 | 255 |
| Employee cost | 63.90 | 60.76 | 53.34 | 49.32 | 40.07 | 35.76 | 35.35 |
| EBITDA | 30.01 | 43.72 | 41.33 | 51.99 | 40.97 | 34.58 | 22.62 |
| EBITDA margin | +8.0% | +11.5% | +11.3% | +13.1% | +12.3% | +11.3% | +8.1% |
| Depreciation | 19.98 | 20.11 | 15.95 | 17.47 | 16.03 | 15.79 | 14.41 |
| Interest | 13.20 | 11.39 | 6.92 | 5.58 | 8.31 | 10.90 | 12.65 |
| Profit before tax | 8.21 | 18.00 | 23.64 | 35.35 | 21.03 | 10.23 | 0.08 |
| Tax | 2.37 | 5.84 | 6.39 | 10.92 | 6.49 | 2.91 | (3.22) |
| Net profit | 4.35 | 11.92 | 17.26 | 24.43 | 14.54 | 11.03 | 3.31 |
| Net profit margin | +1.2% | +3.1% | +4.7% | +6.1% | +4.4% | +3.6% | +1.2% |
| EPS (βΉ) | 1.09 | 2.50 | 3.54 | 5.01 | 8.96 | 4.51 | 2.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 53.50 | 48.73 | 48.73 | 48.73 | 16.24 | 16.24 | 16.18 |
| Reserves & surplus | 240 | 202 | 190 | 152 | 159 | 145 | 138 |
| Shareholders' funds (net worth) | 296 | 252 | 239 | 200 | 176 | 161 | 154 |
| Minority interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Secured loans | 120 | 112 | 106 | 59.57 | 51.31 | 81.07 | 89.44 |
| Unsecured loans | 6.08 | 5.63 | 5.42 | 2.59 | 2.13 | 1.25 | 0.41 |
| Total debt | 127 | 118 | 112 | 62.16 | 53.44 | 82.32 | 89.85 |
| Total liabilities | 423 | 370 | 351 | 262 | 229 | 243 | 244 |
| Assets | |||||||
| Gross block | 290 | 275 | 267 | 199 | 180 | 165 | 159 |
| Net block | 162 | 164 | 161 | 109 | 106 | 107 | 116 |
| Capital work in progress | 95.53 | 70.46 | 42.28 | 26.99 | 11.75 | 10.68 | 9.62 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Inventories | 93.77 | 86.47 | 81.26 | 53.71 | 75.28 | 54.35 | 56.39 |
| Sundry debtors | 109 | 107 | 100 | 95.25 | 89.52 | 72.25 | 67.93 |
| Cash & bank balances | 43.41 | 2.49 | 10.46 | 7.52 | 4.97 | 8.35 | 3.95 |
| Loans & advances | 29.58 | 35.42 | 35.76 | 34.48 | 42.36 | 56.81 | 53.76 |
| Total current assets | 276 | 231 | 228 | 191 | 212 | 192 | 182 |
| Total current liabilities | 106 | 90.93 | 86.21 | 74.26 | 112 | 81.71 | 81.01 |
| Net working capital | 170 | 140 | 141 | 117 | 100 | 110 | 101 |
| Total assets | 423 | 370 | 351 | 262 | 229 | 243 | 244 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 1.95 | 9.60 | 6.42 | 3.42 | 1.39 | 1.46 | 0.50 |
| Net cash from operating activities | 49.53 | 41.15 | 16.28 | 37.52 | 49.21 | 31.85 | 21.92 |
| Net cash from investing activities | (54.54) | (39.70) | (72.63) | (35.06) | (14.21) | (5.95) | (18.44) |
| Net cash from financing activities | 28.19 | (9.10) | 59.53 | 0.55 | (32.97) | (25.97) | (2.51) |
| Net change in cash | 23.18 | (7.65) | 3.18 | 3.00 | 2.03 | (0.07) | 0.96 |
| Closing cash | 43.41 | 2.49 | 10.46 | 7.52 | 4.97 | 8.35 | 3.95 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -1.2% | +3.2% | -7.8% | +19.5% | +8.5% | +10.6% | - |
| EBITDA growth | -31.4% | +5.8% | -20.5% | +26.9% | +18.5% | +52.9% | - |
| PBT growth | -54.4% | -23.9% | -33.1% | +68.1% | +105.6% | - | -99.6% |
| Net income growth | -63.5% | -30.9% | -29.4% | +68.0% | +31.8% | +233.2% | - |
| Revenue CAGR (3Y) | -2.1% | +4.4% | +6.1% | +12.8% | -0.2% | +4.0% | +5.7% |
| EBITDA CAGR (3Y) | -16.7% | +2.2% | +6.1% | +32.0% | -0.9% | -0.2% | -10.4% |
| Profitability & leverage | |||||||
| Net income margin | +1.6% | +3.2% | +4.7% | +6.1% | +4.4% | +2.4% | +1.2% |
| Return on capital employed | +4.8% | +8.2% | +10.0% | +16.7% | +12.4% | +10.8% | +5.4% |
| Return on net worth | +1.6% | +5.0% | +7.9% | +13.0% | +8.7% | +7.0% | +2.2% |
| Debt / equity | 0.45 | 0.47 | 0.40 | 0.31 | 0.40 | 0.55 | 0.55 |
| Long-term debt / equity | 0.22 | 0.23 | 0.20 | 0.19 | 0.21 | 0.24 | 0.25 |
| Interest cover | 131.61 | 48.24 | 27.27 | 16.16 | 33.32 | 58.01 | 153.89 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.33 | 1.40 | 1.58 | 2.10 | 1.93 | 1.89 | 1.88 |
| Inventory turnover | 4.15 | 4.52 | 5.44 | 6.18 | 5.14 | 5.55 | 4.98 |
| Debtors turnover | 3.47 | 3.66 | 3.76 | 4.31 | 4.12 | 4.38 | 3.45 |
| EPS (βΉ) | 1.09 | 2.50 | 3.54 | 5.01 | 8.96 | 4.51 | 2.04 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 54.90 | 51.49 | 49.00 | 41.12 | 108.18 | 98.97 | 95.06 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 104 | 93.05 | 103 | 108 | 88.39 | 71.43 | 109 | 95.40 |
| Revenue growth (YoY) | +17.9% | +30.3% | -5.2% | +13.0% | -1.5% | -12.9% | - | - |
| Other income | 2.29 | 0.99 | 6.16 | 1.71 | 2.04 | 1.48 | 1.55 | 1.76 |
| Total expenses | 99.10 | 90.64 | 96.28 | 95.31 | 82.22 | 67.09 | 93.28 | 83.63 |
| EBITDA | 5.12 | 2.41 | 6.57 | 12.50 | 6.17 | 4.34 | 15.24 | 11.77 |
| EBITDA margin | +4.9% | +2.6% | +6.4% | +11.6% | +7.0% | +6.1% | +14.0% | +12.3% |
| Depreciation | 6.26 | 5.17 | 4.90 | 4.85 | 4.83 | 4.79 | 5.23 | 4.77 |
| Interest | 3.94 | 3.64 | 3.31 | 3.43 | 3.16 | 3.30 | 2.91 | 2.73 |
| Profit before tax | (2.79) | (5.41) | 4.52 | 5.93 | 0.22 | (2.27) | 8.65 | 6.03 |
| Tax | (0.65) | (1.55) | 1.24 | 1.67 | 0.11 | (0.59) | 3.23 | 1.68 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 370 | 376 | 365 | 397 | 329 | 304 | 274 |
| Revenue growth | -1.4% | +2.8% | -7.8% | +20.4% | +8.5% | +10.7% | - |
| Other income | 11.39 | 5.62 | 4.69 | 6.43 | 4.51 | 2.45 | 4.66 |
| Total expenses | 341 | 332 | 325 | 345 | 292 | 272 | 255 |
| Employee cost | 60.10 | 56.41 | 50.81 | 46.47 | 38.63 | 34.48 | 34.58 |
| EBITDA | 29.57 | 43.27 | 40.09 | 51.20 | 37.93 | 31.64 | 19.79 |
| EBITDA margin | +8.0% | +11.5% | +11.0% | +12.9% | +11.5% | +10.4% | +7.2% |
| Depreciation | 19.37 | 19.89 | 14.83 | 16.13 | 14.84 | 14.61 | 13.27 |
| Interest | 13.20 | 11.39 | 6.92 | 5.58 | 8.31 | 10.89 | 12.65 |
| Profit before tax | 8.39 | 17.61 | 23.03 | 35.92 | 19.29 | 8.59 | (1.47) |
| Tax | 2.44 | 5.87 | 6.28 | 10.91 | 6.28 | 2.97 | (3.22) |
| Net profit | 4.39 | 11.66 | 16.76 | 25.01 | 13.01 | 9.01 | 1.76 |
| Net profit margin | +1.2% | +3.1% | +4.6% | +6.3% | +4.0% | +3.0% | +0.6% |
| EPS (βΉ) | 1.11 | 2.41 | 3.44 | 5.13 | 8.01 | 3.46 | 1.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 53.50 | 48.73 | 48.73 | 48.73 | 16.24 | 16.24 | 16.18 |
| Reserves & surplus | 230 | 194 | 183 | 145 | 154 | 141 | 136 |
| Shareholders' funds (net worth) | 286 | 245 | 232 | 194 | 170 | 157 | 152 |
| Secured loans | 120 | 112 | 106 | 59.57 | 51.31 | 81.07 | 89.44 |
| Unsecured loans | 6.08 | 5.63 | 5.42 | 2.59 | 2.13 | 1.25 | 0.41 |
| Total debt | 127 | 118 | 112 | 62.16 | 53.44 | 82.32 | 89.85 |
| Total liabilities | 413 | 362 | 344 | 256 | 224 | 239 | 242 |
| Assets | |||||||
| Gross block | 281 | 268 | 260 | 192 | 174 | 160 | 153 |
| Net block | 160 | 164 | 160 | 107 | 103 | 103 | 111 |
| Capital work in progress | 89.40 | 65.67 | 40.25 | 26.26 | 11.42 | 10.46 | 9.62 |
| Investments | 17.66 | 13.04 | 8.23 | 8.18 | 8.18 | 8.08 | 8.08 |
| Inventories | 93.77 | 86.47 | 81.26 | 53.71 | 75.28 | 54.35 | 56.39 |
| Sundry debtors | 92.28 | 93.68 | 100 | 88.36 | 80.89 | 63.95 | 63.34 |
| Cash & bank balances | 37.00 | 0.82 | 0.75 | 2.21 | 2.09 | 7.86 | 2.83 |
| Loans & advances | 29.38 | 35.38 | 35.61 | 34.37 | 42.33 | 56.81 | 53.73 |
| Total current assets | 252 | 216 | 218 | 179 | 201 | 183 | 176 |
| Total current liabilities | 102 | 90.77 | 88.68 | 73.72 | 112 | 80.91 | 80.64 |
| Net working capital | 151 | 126 | 129 | 105 | 89.07 | 102 | 95.65 |
| Total assets | 413 | 362 | 344 | 256 | 224 | 239 | 242 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.36 | 0.17 | 1.11 | 0.54 | 0.90 | 0.67 | 0.36 |
| Net cash from operating activities | 47.66 | 50.60 | 11.47 | 35.23 | 47.03 | 31.90 | 21.29 |
| Net cash from investing activities | (57.41) | (41.31) | (71.94) | (35.21) | (14.42) | (5.70) | (18.82) |
| Net cash from financing activities | 28.19 | (9.10) | 59.53 | 0.55 | (32.97) | (25.96) | (2.16) |
| Net change in cash | 18.43 | 0.19 | (0.94) | 0.57 | (0.36) | 0.23 | 0.31 |
| Closing cash | 37.00 | 0.82 | 0.75 | 2.21 | 2.09 | 7.86 | 2.83 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -1.4% | +2.8% | -7.8% | +20.4% | +8.5% | +10.7% | - |
| EBITDA growth | -31.7% | +7.9% | -21.7% | +35.0% | +19.9% | +59.9% | - |
| PBT growth | -52.4% | -23.5% | -35.9% | +86.2% | +124.6% | +9998.0% | - |
| Net income growth | -62.4% | -30.4% | -33.0% | +92.2% | +44.4% | +411.9% | - |
| Revenue CAGR (3Y) | -2.2% | +4.5% | +6.4% | +13.1% | -0.2% | +3.8% | +5.3% |
| EBITDA CAGR (3Y) | -16.7% | +4.5% | +8.2% | +37.3% | -3.7% | -2.3% | -14.4% |
| Profitability & leverage | |||||||
| Net income margin | +1.6% | +3.1% | +4.6% | +6.3% | +4.0% | +1.9% | +0.6% |
| Return on capital employed | +4.9% | +8.2% | +10.0% | +17.3% | +11.9% | +10.2% | +4.7% |
| Return on net worth | +1.7% | +4.9% | +7.9% | +13.7% | +8.0% | +5.8% | +1.2% |
| Debt / equity | 0.46 | 0.48 | 0.41 | 0.32 | 0.41 | 0.56 | 0.55 |
| Long-term debt / equity | 0.16 | 0.17 | 0.15 | 0.16 | 0.21 | 0.16 | 0.20 |
| Interest cover | 129.41 | 48.72 | 27.40 | 15.91 | 35.99 | 63.95 | 194.02 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.35 | 1.42 | 1.62 | 2.17 | 1.98 | 1.94 | 1.94 |
| Inventory turnover | 4.11 | 4.48 | 5.42 | 6.15 | 5.08 | 5.48 | 4.92 |
| Debtors turnover | 3.98 | 3.88 | 3.88 | 4.69 | 4.55 | 4.77 | 3.57 |
| EPS (βΉ) | 1.11 | 2.41 | 3.44 | 5.13 | 8.01 | 3.46 | 1.08 |
| Dividend per share (βΉ) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (βΉ) | 53.07 | 49.90 | 47.60 | 39.85 | 104.73 | 96.69 | 93.79 |
Timeline of Zim Labs
4 dated milestones of Zim Labs across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Zim Labs is founded.
- Funding First funding round of $8.2M.
- Funding Latest funding round, Grant,.
- IPO Lists on the stock exchange (IPO).
Competitors of Zim Labs
Zim Labs has 2 listed competitors in our database, 1 of them funded. They include Inventia Healthcare and Halewood Laboratories.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inventiahealthcare.com | 1985 | Mumbai, India | $42.49M | 980 | Oral solid drug delivery systems are manufactured and developed. | |
| halewoodlabs.com | 1984 | Ahmedabad, India | 348 | Provides contract manufacturing services for food, pharmaceuticals, and related products globally. |
Detailed competitors of Zim Labs
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Zim Labs
The website of Zim Labs (zimlab.in) receives about 12.1K visits a month and ranks #1,856,720 among all websites worldwide, #2,538 in Biotechnology and Pharmaceuticals.
- Monthly visits12.1K
- Unique visitors5.5K
per month
- Global rank#1,856,720
among all websites
- Category rank#2,538
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit2.0
- Average visit25 sec
- DevicesDesktop 24% Β· Mobile 76%
Websites whose visitors overlap most with Zim Labs. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| naturalremedy.com | 100% | 42.1K | #964,146 | View details | |
| ondrugdelivery.com | 100% | #833,579 | View details | ||
| cooperpharma.com | 95% | 17.9K | #1,398,892 | View details | |
| akums.in | 91% | 25.5K | #1,037,095 | View details | |
| bionova.co.in | 84% | 13.3K | #2,213,654 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 11 similar websites and full traffic analytics for Zim Labs
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Zim Labs (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zim Labs
Complete news archive for Zim Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zim Labs
Zim Labs was founded in 1989 and raised its 1st funding round 24 years after it was founded.
Zim Labs is headquartered in Nagpur, India. It is registered at Nagpur, Maharashtra, India.
Zim Labs is a funded company, having raised a total of $8.2M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.2M, raised on Jan 2013.
Zim Labs has 577 employees.
The primary company behind Zim Labs, Zim Laboratories Limited., reported revenue of βΉ386 Cr for FY 2026, down 1% year on year.
Zim Labs was founded in 1989 and is based in Nagpur, India, within the pharmaceutical sector. Various solid and semisolid dosage forms, such as granules, pellets with sustained, modified, or extended release, taste-masked powders, suspensions, tablets, capsules, and oral thin films, are developed and manufactured. Services provided include drug release modifications, solubility enhancement, and taste masking for pharmaceutical applications.
Zim Labs's top competitors include Inventia Healthcare and Halewood Laboratories.
Zim Labs offers Oral Thin Films, Pre-Formulation Intermediates, and Finished Formulations.
Yes, Zim Labs is publicly traded on NSE under the ticker symbol ZIMLAB.
Zim Labs has 1 investor. Key investors include Ashmore.
Zim Labs operates through Zim Laboratories Limited..
The legal entities of Zim Labs currently have 10 directors, including Zulfiquar Murtaza Kamal, Prakash Pralahadrao Sapkal, Niraj Pukhraj Dhadiwal and others.
